Chemotherapy News and Research

Latest Chemotherapy News and Research

Avastin increases tumor response rates in breast cancer patients before surgery

Amid the controversy surrounding the Food and Drug Administration's ruling that Avastin should no longer be used to treat metastatic breast cancer, a new multinational Phase III clinical trial shows that Avastin significantly increased tumor response rates in breast cancer patients when given before surgery.

24 Aug 2011

Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma

Seattle Genetics, Inc. today announced that it has initiated a phase II clinical trial of ADCETRIS for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas, including diffuse large B-cell lymphoma, peripheral T-cell lymphoma and other less common lymphoma subtypes.

24 Aug 2011

KU professor to create patient-friendly lung cancer treatment

A Kansas State University professor is trying to create a patient-friendly treatment to help the more than 220,000 people who are diagnosed with lung cancer each year.

23 Aug 2011

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

Helsinn, a Swiss-based pharmaceutical company, announced today that its US subsidiary, Helsinn Therapeutics, has enrolled the first patient in the company's pivotal Phase III clinical program of anamorelin HCl for the treatment of anorexia/cachexia in patients with advanced non-small cell lung cancer.

23 Aug 2011

Prescription drug shortages forcing docs, pharmacists to scramble

Record shortages of prescription drugs in the United States are forcing pharmacists and doctors to scramble to find medications for their patients, suitable alternatives or to delay potentially lifesaving treatments.

23 Aug 2011

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.

23 Aug 2011

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Symphogen A/S today announced the initiation of a Phase 2 clinical trial to investigate the safety and efficacy of Sym004 in patients who have failed anti-EGFR monoclonal antibody (mAb)-based therapy, with recurrent and/or metastatic squamous cell carcinoma of the head and neck.

23 Aug 2011

Radium-223 chloride granted FDA Fast Track designation for treatment of CRPC

Algeta ASA, a company focused on the development of novel targeted cancer therapeutics, today announced that radium-223 chloride has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of castration-resistant (hormone refractory) prostate cancer in patients with bone metastases.

23 Aug 2011

New open access journal on malaria

A post in the "Malaria Matters" blog announces "a new open access journal on malaria: Malaria Chemotherapy, Control and Elimination," which "has been recently launched by Ashdin Publishing."

22 Aug 2011

Nurse safety measures around highly toxic drugs needed

Nearly 17 percent of nurses who work in outpatient chemotherapy infusion centers reported being exposed on their skin or eyes to the toxic drugs they deliver, according to a new study from the University of Michigan Comprehensive Cancer Center.

22 Aug 2011

First computerized genome-scale model of cancer cell metabolism

Scientists are constantly on the hunt for treatments that can selectively target cancer cells, leaving other cells in our bodies unharmed.

22 Aug 2011

WHO spokesperson addresses health, medical needs for Libya on PBS NewsHour

The WHO "is rushing to secure medical supplies for Libya" after the Dutch government on Monday released nearly $145 million in frozen assets from Libyan leader Moammar Qaddafi's regime in response to a direct WHO appeal, PBS NewsHour reports.

20 Aug 2011

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

Seattle Genetics, Inc. today announced that the U.S. Food and Drug Administration has granted accelerated approval of ADCETRISTM for two indications: (1) the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates, and (2) the treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.

20 Aug 2011

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

The U.S. Food and Drug Administration today approved Adcetris to treat Hodgkin lymphoma and a rare lymphoma known as systemic anaplastic large cell lymphoma.

20 Aug 2011

Temple University, URMC partner to translate novel medical research into new drugs

The University of Rochester Medical Center (URMC) and Temple University School of Pharmacy have announced a partnership that will help translate novel medical research into new drugs for treating diseases.

19 Aug 2011

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

DARA BioSciences, Inc. announced today that its investigational drug KRN5500 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of chemotherapy-induced neuropathic pain in patients with cancer.

19 Aug 2011

EMA accepts Merck and ARIAD's MAA for ridaforolimus to treat metastatic bone sarcomas

Merck, known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has completed its administrative validation process for the regulatory application for ridaforolimus, an investigational oral mTOR inhibitor developed for the treatment of metastatic soft-tissue or bone sarcomas in patients who had a favorable response to chemotherapy.

18 Aug 2011

New leukemia drug in early clinical testing offers some clues for better treatment

While testing a new drug designed to treat chronic leukemia, researchers at Cleveland Clinic discovered new markers that could identify which patients would receive maximum benefit from the treatment.

18 Aug 2011

Herbal supplements may weaken the effect of chemotherapy drugs

Acai berry, cumin, herbal tea, turmeric and long-term use of garlic - all herbal supplements commonly believed to be beneficial to your health - may negatively impact chemotherapy treatment according to a new report presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago this summer.

18 Aug 2011

New process may eliminate need for full genome sequencing for cancer patients

People at risk for a certain form of colon and other types of cancer may soon have a better chance at surviving or even avoiding the diseases, thanks to a new study done by the Intermountain Clinical Genetics Institute at LDS Hospital.

18 Aug 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Avastin increases tumor response rates in breast cancer patients before surgery

Seattle Genetics initiates ADCETRIS phase II trial in CD30-positive non-Hodgkin lymphoma

KU professor to create patient-friendly lung cancer treatment

Helsinn begins enrollment in anamorelin Phase III trial for NSCLC-associated anorexia/cachexia

Prescription drug shortages forcing docs, pharmacists to scramble

Spinifex secures AU$6.25 million in expanded Series B funding

Symphogen initiates Sym004 Phase 2 trial in squamous cell carcinoma of head and neck cancer

Radium-223 chloride granted FDA Fast Track designation for treatment of CRPC

New open access journal on malaria

Nurse safety measures around highly toxic drugs needed

First computerized genome-scale model of cancer cell metabolism

WHO spokesperson addresses health, medical needs for Libya on PBS NewsHour

FDA approves Seattle Genetics ADCETRIS drug to treat Hodgkin lymphoma, ALCL

Seattle Genetics receives FDA approval for Adcetris to treat Hodgkin lymphoma, ALCL

Temple University, URMC partner to translate novel medical research into new drugs

FDA grants Fast Track designation for DARA's KRN5500 neuropathic pain relief drug

EMA accepts Merck and ARIAD's MAA for ridaforolimus to treat metastatic bone sarcomas

New leukemia drug in early clinical testing offers some clues for better treatment

Herbal supplements may weaken the effect of chemotherapy drugs

New process may eliminate need for full genome sequencing for cancer patients

Cancer Research - Second Edition eBook

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Newsletters you may be interested in